房颤合并慢性肾病患者的华法林使用与抗凝控制
结果显示华法林使用率随CKD加重而下降(57.2%-46.4%),透析患者TTR≥60%者仅21%,且INR<1.5或>3.5的时间高达30%。
要点
- 华法林使用率随CKD严重程度增加而降低,但透析患者使用率反升至62.3%。
- INR监测强度各CKD分层相似,但TTR≥60%的比例随CKD加重而下降。
- 透析患者INR<1.5或>3.5的时间达30%,其中12%时间INR>3.5。
核心结论
- 房颤合并中重度CKD(包括透析)患者尽管INR监测强度相当,TTR显著降低,提示需更强化华法林管理或改用直接口服抗凝药。
主要发现
- 华法林使用率随CKD严重程度增加而下降(57.2%-46.4%),透析患者使用率为62.3%。
- TTR≥60%的比例随CKD加重而下降,透析患者仅21%达到TTR≥60%。
- 透析患者INR<1.5或>3.5的时间占30%,其中12%时间INR>3.5。
- 低TTR状态在透析患者中持续长达3年。
关键数值与推荐
- TTR≥60%为达标阈值,透析患者达标率21%。
- INR<1.5或>3.5定义为显著超出范围,透析患者占30%时间。
临床怎么用
- 对房颤合并中重度CKD患者应加强华法林抗凝管理或考虑直接口服抗凝药等替代治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate warfarin prescription, quality of international normalised ratio (INR) monitoring and of INR control in patients with atrial fibrillation (AF) and chronic kidney disease (CKD). METHODS: We performed a retrospective cohort study of patients with newly diagnosed AF in the Veterans Administration (VA) healthcare system. We evaluated anticoagulation prescription, INR monitoring intensity and time in and outside INR therapeutic range (TTR) stratified by CKD. RESULTS: Of 123 188 patients with newly diagnosed AF, use of warfarin decreased with increasing severity of CKD (57.2%-46.4%), although it was higher among patients on dialysis (62.3%). Although INR monitoring intensity was similar across CKD strata, the proportion with TTR≥60% decreased with CKD severity, with only 21% of patients on dialysis achieving TTR≥60%. After multivariate adjustment, the magnitude of TTR reduction increased with CKD severity. Patients on dialysis had the highest time markedly out of range with INR <1.5 or >3.5 (30%); 12% of INR time was >3.5, and low TTR persisted for up to 3 years. CONCLUSIONS: There is a wide variation in anticoagulation prescription based on CKD severity. Patients with moderate-to-severe CKD, including dialysis, have substantially reduced TTR, despite comparable INR monitoring intensity. These findings have implications for more intensive warfarin management strategies in CKD or alternative therapies such as direct oral anticoagulants.
引用
- Yang F, Hellyer JA, Than C, et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart. 2016. PMID: 27852694. doi:10.1136/heartjnl-2016-309266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。